Tag:
immununotherapy
Latest Headlines
Latest Headlines
Genitope suspends cancer work, looks to alternatives
After reviewing a failed late-stage trial of MyVax for Hodgkins lymphoma, Genitope has decided to suspend development work and focus on alternatives like its antibody program. MyVax had already
ALSO NOTED: New Roche CEO maps strategy; StemCells backs off buyout; and much more...
> Roche's incoming CEO, Severin Schwan, sees a continued emphasis on personalized medicine and says he also isn't anticipating any big mergers.
Press Release: Introgen Therapeutics's INGN 225 Molecular Cancer Vaccine Demonstrates Promising Results In Phase 2 Trial
Press Release: Introgen Therapeutics's INGN 225 Molecular Cancer Vaccine Demonstrates Promising Results In Phase 2 Trial
Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
ALSO NOTED: BMS staggered by generic competitor; NicOx hits endpoints; and much more...
> Staggered by generic competition for Plavix , Bristol-Myers Squibb says it saw sales decline by $600 million in the third quarter. In addition, BMS said that one of the federal probes into its conduct is now centered on potential securities violations. …
Dynavax ragweed data fuels big share jump
Shares of Dynavax took off this morning after the developer announced new data demonstrating the effectiveness of its experimental therapy for ragweed allergies. Ragweed allergy sufferers were given the therapy--AIC--for six weeks and typically experienced a reduction in symptoms for 12 months. Dynavax shares jumped 26 percent. "The demonstrated therapeutic properties and safety pave the way for a therapeutic …
Dendreon cuts jobs, focuses on Provenge
Dendreon has announced that it will cut 34 jobs as it refocuses its resources on advancing its lead investigational drug Provenge to market. Provenge is a cellular immunotherapy for the treatment of prostate cancer. In addition, the company announced that Michelle Burris, senior vice president and CFO, will be leaving. Rick Hamm, senior vice president, corporate development and general counsel will oversee financial functions and David Urdal, Ph.D., senior vice president and chief …
SPOTLIGHT: Inex to spin off assets
Vancouver-based Inex Pharmaceuticals plans to spin off its immunotherapy assets and some cash into a new company as it focuses on the development of its oncology therapy Marqibo. Inex would keep a minority stake in the new venture. Report
VC: Raven biotechnologies leads with $48.3M fourth round
Raven biotechnologies leads with $48.3M fourth round.
VIRxSYS closes $31M fifth round
VIRxSYS of Gaithersburg, MD, raised $31 million of venture capital in a final closing of its fifth round. The biotech company used money raised earlier in the round for a Phase I trial of its VRX496 gene-based anti-HIV immunotherapy. Much of the remainder of the money will go to a Phase II trial. VIRxSYS recently recruited Dr. Riku Rautsola as its new CEO. "Dr. Rautsola's track record in biotech suggests a bright future for VIRxSYS and its pipeline of gene-based medicines," said Eric …
